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Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was
caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I)
production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in
patients is not investigated.
Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of
SFTS patients and the healthy population with CBA (Cytometric bead array) assay.
Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF),
interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein
(IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons
(p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS
patients than in mild SFTS patients (p < 0.05).
Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is
correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV
infection in humans and it may play an import role in cytokine storm.
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Background
Severe fever with thrombocytopenia syndrome (SFTS) is
an emerging hemorrhagic fever in East Asia that is
caused by a tick-borne bunyavirus, SFTSV [1]. The
major clinical manifestations of SFTS included acute
fever (≥38 °C), thrombocytopenia, leucopenia, gastro-
intestinal symptoms, central nervous system (CNS)
symptoms, and multiple organ dysfunctions [1–3]. The
case fatality rate of the disease ranged from 12 to 30% in
China and is even higher in Japan [1, 4]. However, the
pathogenic mechanism of the disease was not well
studied. Previous studies suggested that a cytokine
storm might be associated with the development of
the disease [5–7].
Cytokines are a group of small proteins which are es-
sential for fighting off infections. However, overproduc-
tion of cytokines could trigger a dangerous situation
known as a cytokine storm. The nonstructural protein of
SFTSV has been described to inhibit type I interferon
(IFN-I) production in cell culture [8, 9]. Mouse is natur-
ally resistant to SFTSV infection, but IFN-α receptor
(IFNAR) deficient mouse is highly susceptible to SFTSV
infection [10]. These studies suggested that IFN-I may
play an important role in resistance SFTSV infection.
However, the role of IFN-I in resistance SFTSV infec-
tions has not yet been investigated in humans although
the role of other cytokines has been well studied by sev-
eral reports. The aim of this study is to determine the
concentration of IFN-α, a subtype of IFN-I as well as the
concentration of other cytokines in SFTS patients and in
the healthy population. By analyzing the differences in
cytokine concentrations between severe SFTS patents
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and mild SFTS patients and between SFTS patients and
the healthy population, we attempted to determine the
role of IFN-α and other cytokines in the pathogenesis of
SFTS.
Methods
Patient sera and clinical information
The SFTS patients included in this study had met one or
more of the following criteria: (1) SFTSV was isolated
from the patient’s serum, (2) SFTSV RNA was detected
from the patient’s serum by a quantitative reverse-
transcriptase polymerase chain reaction (RT-PCR) and
(3) seroconversion or a 4-fold increase of antibody titers
was detected between the acute and convalescent sera of
the same patient. The sera of SFTS patients used in this
study were obtained during the acute phase of the dis-
ease (within 2 weeks since onset). The sera of healthy
persons were obtained from the persons who came to
the hospital for physical examination. In accordance
with the illness severity, the patients were divided into
severe and mild groups [2, 3, 6]. Severe SFTS cases were
defined as patient who required admission to an intensive
care unit and met at least one of the following criteria: (1)
acute lung injury (ALI) /acute respiratory distress syn-
drome (ARDS), (2) heart failure, (3) acute renal failure, (4)
encephalitis, (5) shock, (6) septicemia, (7) disseminated
intravascular coagulation (DIC), or (8) death.
Multiplex cytokine assay
The concentrations of serum cytokines were tested with
BD™ human soluble protein master buffer kits and BD™
CBA flex sets according to the manufacturer’s instruc-
tions (BD Bioscience-PharMingen, San Diego, CA). The
cytokines assayed in this study included tumor necrosis
factor (TNF-α), granulocyte colony-stimulating factor
(G-CSF), interferon-γ (IFN-γ), IFN-α, macrophage inflam-
matory protein (MIP-1α), interleukin-6 (IL-6), IL-10,
interferon-inducible protein (IP-10), monocyte chemo-
attractant protein (MCP-1), and regulated upon activation
normal T cell expressed and secreted factor (RANTES).
Statistical analysis
The statistical analysis was performed using SPSS soft-
ware 18.0 for Windows. Means for continuous variables
were compared using independent-group Student’s t tests
when the data were normally distributed; otherwise, the
Wilcoxon rank sum test was used. The categorical vari-




Fifty SFTS patients who were confirmed to be infected
by SFTSV previously were enrolled in this study [11].
The mean age was 61.2 (SD = 10.9) years old, and 17
(34.0%) of them were male. In addition to the pa-
tients, thirty-eight age and sex matched healthy indi-
viduals were also enrolled. The mean age of healthy
individuals was 62.7 (SD = 13.2) years old, and 14
(36.8%) of them were male. There were no significant
differences between patients and normal subjects on
the distribution of age and gender (Table 1). Among
the fifty patients, thirty-six of them were mild pa-
tients and fourteen were severe patients. There was
no difference on gender distribution between the se-
vere patients (male, 28.6%) and the mild patients
(male, 36.1%). However, the severe patients were sig-
nificantly older than the mild patients (67.0 VS 59.5,
p = 0.003) (Table 2).
Cytokine concentrations
Comparison of cytokine concentrations between SFTS
patients and healthy population
Except for RANTES, the concentrations of all tested
cytokines including TNF-α, G-CSF, IFN-γ, IFN-α,
MIP-1α, IL-6, IL-10, IP-10, and MCP-1 were signifi-
cantly higher in SFTS patients than those in healthy
individuals (p < 0.05) (Table 1). The concentration of
IFN-γ, IFN-α, TNF-α, G-CSF, MCP-1, and IL-6 were
moderately increased in SFTS patients than in the
healthy population with 1 to 7 fold increases, whereas, the
concentration of MIP-1α, IP-10, and IL-10 were ex-
tremely increased in SFTS patients than that in
healthy individuals with 42 to 1228 fold increases.
RANTES was the only cytokine that was decreased in
SFTS patients than in healthy persons (4676.3 VS7220.0,
p = 0.003).
Table 1 Comparison of age, gender and cytokine concentrations
between SFTS patients and healthy populationa
Characteristic Patients (n = 50) Healthy Individuals (n = 38) p Value
Sex, male, n (%) 17 (34.0) 14 (36.8) 0.782
Age, year,
mean (SD)
61.2 (10.9) 62.7 (13.2) 0.554
TNF-α 1.2 (0.6–1.6) 0.0 (0.0–0.3) 0.001
G-CSF 7.6 (5.5–18.7) 4.0 (3.5–4.4) 0.027
IFN-γ 10.8 (4.6–34.5) 2.2 (1.7–2.6) 0.001
IFN-α 14.1 (6.5–29.5) 2.4 (1.9–2.8) 0.001
MIP-1α 16.4 (5.0–46.7) 0.1 (0.0–2.0) 0.045
IL-6 28.1 (10.7–70.5) 4.0 (3.3–6.6) 0.001
MCP-1 156.7 (88.9–407.9) 37.7 (20.7–61.3) 0.005
IL-10 1228.4 (88.8–3960.9) 1.0 (0.8–1.7) 0.002
IP-10 2718.7 (1389.9–5278.9) 65.1 (37.6–168.5) 0.001
RANTES 4676.3 (2982.4–7555.5) 7220.0 (5468.7–100115.6) 0.003
Unit: pg/ml; aValues are listed as median range unless otherwise noted; SD,
standard deviation
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Comparison of cytokine concentrations between severe and
mild SFTS patients
The results showed that severe SFTS patients were
significantly older than the mild patients. In order to
confirm whether age is an influencing factor for the
concentrations of cytokines, the healthy individuals
were divided into two parts according to their ages.
There was no significant difference between the two
parts on the concentration of cytokines (fifty percent
of them were older than 65 years, data not shown).
The concentrations of G-CSF, IFN-α, IFN-γ, MIP-1α,
IL-6, and IP-10 were significantly increased in severe
SFTS patients than in mild patients (p < 0.05);
whereas the concentrations of TNF-α, MCP-1, IL-10
and RANTES did not significantly differ between the
two groups of patients (Table 2). Severe SFTS pa-
tients exhibited a moderate 1.6 to 6.7-fold increase in
cytokine concentrations when compared to mild SFTS
patients.
Discussion
Cytokines, a class of small molecule proteins with a
broad range of biological activities, are mainly synthe-
sized and secreted by immune cells [12]. According to
their functions, cytokines can be divided into the follow-
ing categories: chemokine, interferon, interleukin, colony
stimulating factor, tumor necrosis factor, transforming
growth factor and growth factor. They act through re-
ceptors and play an important role in host immune re-
sponse to infections and cancer. Viral infections can
stimulate the body to produce immune responses, in-
cluding the innate immune response and adaptive im-
mune response. TNF-α and IFNs are involved in the
innate immune response, which is the first line of
defense against viral infections. In the subsequent
adaptive immune response, IL, CSF, chemokine and
other cytokines play an important role [13].
The concentrations of most cytokines have been re-
ported previously [5–7]. Our results were consistent
with previous studies, indicating that the cytokine level
of G-GSF, IFN-γ, IL-6, IL-10, TNF-α, MIP-1α, MCP-1,
and IP-10 were significantly higher in SFTS patients
than in the healthy controls. Moreover, the levels of G-
CSF, IFN-γ, MIP-1α, IL-6, and IP-10 were significantly
higher in severe SFTS patients than the mild patients.
Interferons are glycoprotein secreted by mononuclear
leukocytes and lymphocytes in response to pathogens,
such as viruses and bacteria, or tumor cells [14]. Based
on the type of receptor, human interferons have been
classified into three major types: interferon type I, inter-
feron type II and interferon type III. In a typical sce-
nario, a virus-infected cell will release interferons
causing nearby cells to heighten their anti-virus defenses.
IFN-α proteins produced by leukocytes [15] is a member
of the type I interferon family, a multi-gene cytokine
family that includes IFN-α, IFN-β, IFN-ε, IFN-τ, IFN-κ,
IFN-ω, IFN-δ and IFN-ζ in humans [16]. All IFN-I bind
to a cell surface receptor complex, IFN-α receptor
(IFNAR), consisting of IFNAR1 and IFNAR2 chains
[17, 18]. IFN-I has been found in all mammals and
similar molecules have been found in fish, reptile and
birds [17, 18]. IFN-I has diverse effects on innate and
adaptive immune cells during infections, directly and/or
indirectly through the induction of other mediators [19].
Normal mice are resistant to SFTSV infection, but IFNAR
deficient mice became highly susceptible to SFTSV infec-
tion, suggesting the importance of IFN-I in resistance to
SFTSV infection [10]. However, IFN-I has been shown to
cause immunopathology in some acute viral infections,
such as influenza virus infection [19]. The changes of
IFN-I content during different viral infections varied. The
level of IFN-α was significantly elevated in the serum of
SARS and Hantavirus pulmonary syndrome patients
[20, 21]. However, another study indicated that the
IFN-I response was not notable during hantavirus in-
fection [22]. Given the importance of IFN-I against
viral infections or in immunopathology of viral infec-
tions, it is surprising that only one article reported
the IFN-α2 concentration in the serum of SFTS patients
[2]. Our original hypothesis was that IFN-I should be low
in severe SFTS patients than in mild SFTS patients
because it had the function in defending against viral in-
fection. However, our results showed the opposite, sug-
gesting that high concentrations of IFN-α in SFTS patient
could not control SFTSV, which may actually involve in
cytokine storm. It is interesting to note that in vitro stud-
ies indicated that the non-structural proteins of SFTSV in-
hibits the generation of type I interferon to promote viral
replication [8, 9, 23]. However, our results indicated that
Table 2 Comparison of age, gender and cytokine concentrations
between severe and mild SFTS patientsa
Characteristic Mild patients (n = 36) Severe patients (n= 14) p Value
Sex, male, n (%) 13 (36.1) 4 (28.6) 0.613
Age, year 59.5 (49.3–65.0) 67 (62.0–73.5) 0.003
TNF-α 1.2 (0.7–1.6) 1.3 (0.5–4.0) 0.314
G-CSF 6.9 (5.3–10.6) 20.1 (11.7–49.1) 0.001
IFN-γ 8.8 (3.9–25.1) 54.3 (6.2–90.4) 0.005
IFN-α 11.0 (5.3–18.8) 26.9 (14.3–138.3) 0.001
MIP-1α 12.1 (2.5–30.7) 56.4 (20.6–222.0) 0.001
IL-6 18.3 (7.9–45.8) 121.2 (47.5–272.4) 0.001
MCP-1 141.7 (85.4–339.9) 227.8 (118.6–1185.4) 0.115
IL-10 1188.7 (87.7–2436.2) 3917.0 (106.9–11025.9) 0.210
IP-10 2178.0 (1260.8–3715.6) 5385.2 (3362.3–8394.3) 0.003
RANTES 4855.4 (3070.1–7739.9) 4195.5 (2728.6–6199.0) 0.612
Unit: pg/ml; aValues are listed as median range unless otherwise noted
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the level of IFN-α is significantly higher in SFTS patients
than healthy persons. Moreover, IFN- α is also significant
higher in severe SFTS patients than in mild SFTS patients.
A previous study also indicated that severe SFTS patients
had higher SFTSV viral loads in serum than mild SFTS
patients [24]. Combining the results of our study and the
previous study, we concluded that higher SFTSV viral load
stimulate stronger IFN-α production in vivo, suggesting
that non-structural proteins of SFTSV may be not import-
ant for inhibition of the production of type I INFs in vivo.
Our result was different on IFN-α compared to a previous
study, which showed no significant difference between
severe and mild patients (2). The concentration discrep-
ancy may be caused by different collection stage or storage
condition.
Our results showed that IFN-γ was also correlated to
the severity of SFTSV infection, which is consistent with
a previous study [2]. However, another study indicated
that levels of IFN-γ in non-severe cases were lower than
values detected in healthy individuals [6].
G-CSF stimulates bone marrow to generate granulo-
cytes and release them into the blood stream. It can
stimulate the survival, proliferation, differentiation, and
function of neutrophil precursors and mature neutro-
phils, which have phagocytosis and chemotaxis function
against infection [25]. However, when the body was in-
fected with SFTSV, the white blood cell count would
progressively decrease [26–28]. G-CSF may be produced
to increase white blood cells against SFTSV infection.
Our study indicated that G-CSF is significantly increased
in SFTS patients and it is correlated to the severity of
SFTSV infection.
Interleukins are mainly expressed by leukocytes and
their main functions are to promote the development
and differentiation of T and B lymphocytes, and
hematopoietic cells [29]. IL-6 plays an important role in
inducing B cells to differentiate into plasma cells to pro-
duce antibody [30]. IL-10 down-regulates the immune
response after virus infection by inhibiting IFN-γ pro-
duction, antigen presentation, and macrophage produc-
tion of IL-1, IL-6, and TNF-α. IL-10 induces activated B
cells to secrete large amounts of IgG, IgA, and IgM.
Thus, IL-10 may play an important role in the amplifica-
tion of humoral responses [31]. IL-6 and IL-10 are usu-
ally increased in viral infections. IL-6 and IL-10 were
significantly elevated in Chikungunya fever patients
compared to uninfected persons [32]. IL-10 level was
significantly elevated at the early stage of Ebola infection
[33]. The role of IL-10 in inhibiting antigen-stimulated
T cell proliferation supports the assumption that a T
cell–mediated response is critical for survival of Ebola
virus infected patients [33, 34]. Both IL-6 and IL-10 are
significantly increased in SFTS patients and lL-6, but not
IL-10 is correlated to the severity of SFTSV infection.
TNF-α is a monocyte-derived cytotoxin that can dir-
ectly kill tumor cells and has no obvious toxicity to nor-
mal cells. By binding to the corresponding receptor, it
participates in host antiviral response [35]. Consistent
with previous studies, we demonstrate that the concen-
tration of TNF-α is extremely low in healthy individuals
(median = 0, range: 0-0.3 pg/ml); however, even in severe
patients, its concentration is only 1.3 pg/ml (range: 0.5-
4.0). There was no significant difference between the
severe SFTS patients and the mild SFTS patients which
suggested that TNF-α may not play an important role in
the progress of infection as previously expected.
MIP-1α, MCP-1, and IP-10 are chemokines, a family
of small signaling proteins mainly secreted by white
blood cells. The major role of chemokine is to act as a
chemoattractant to guide the migration of cells [36].
During the processes of immune surveillance, chemo-
kine can regulate cells of the immune system, such as
directing lymphocytes to the lymph nodes so they can
screen for invasion of pathogens by interacting with
antigen-presenting cells residing in these tissues [37].
Our study showed that the increase of both MIP-1 and
IP-10 are significantly correlated to the severity of
SFTSV infection. Several previous studies have also re-
ported increase of these cytokines in SFTS patients [2, 6].
RANTES, a known chemoattractant for monocyte and
T cells, is produced by many cell types, including endothe-
lial cells and macrophages [38]. RANTES have an essential
role in activation and proliferation of antigen-specific T
cells [39]. It was the only indicator we studied that had a
higher level in healthy subjects. Furthermore, its concen-
tration was decreased in severe patients compared to the
mild patients. This result was completely opposite with
other cytokines. In a previous study, the level of RANTES
decreased in SFTS patient which was consistent with our
result [5]. However, in another study the concentration of
RANTES in patients’ sera was obviously increased com-
pared to healthy persons [6]. The concentration discrep-
ancy of RANTES in different studies may be caused by
collecting the samples in different stage of infection.
Cytokine storm is a potentially fatal immune reaction
consisting of a positive feedback loop between cytokine
and white blood cells, with highly elevated levels of vari-
ous cytokines [40]. Studies found that a variety of patho-
gen infections can cause a cytokine storm, which may
cause acute respiratory distress syndrome and multiple
organ failure [5, 41–43]. Previous studies demonstrated
that SFTSV infection induced a cytokine storm with ab-
normally expressed cytokine profiles, which might be
associated with the disease severity [5, 6, 44]. Consistent
with our study, the elevated cytokines in those above
studies included IP-10, G-CSF, IL-6, IL-10, MCP-1, and
MIP-1α. However, the differences of TNF-α and IFN-γ
concentration between severe and mild SFTS patients
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were varied in different studies. Deng, et al showed that
the concentrations of TNF-α and IFN-γ were signifi-
cantly higher in severe cases than non-severe cases [6].
However, there were people who also indicated that the
production of TNF-α and IFN-γ during the acute phase
were only slightly elevated in severe cases [5]. In this
study, most of the cytokines including G-CSF, IFN-γ,
IFN-α, MIP-1α, IL-6, and IP-10 were correlated to the
severity of SFTSV infection.
Conclusion
Our results indicated that IFN-α as well as other cyto-
kines including G-CSF, IFN-γ,, MIP-1α, IL-6, and IP-10
were correlated to the severity of SFTSV infection, sug-
gesting that type I interferon may not play a significant
role in resistance SFTSV infection in humans and it may
play an import role in cytokine storm involved in the
pathogenesis of SFTS.
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